NCT02993302 is a Phase 2 clinical trial of 1α-D3 in Graves Disease, sponsored by Dr Cipto Mangunkusumo General Hospital.

Who is sponsoring NCT02993302?

NCT02993302 is sponsored by Dr Cipto Mangunkusumo General Hospital.

What drugs are being tested in NCT02993302?

Interventions in NCT02993302: 1α-D3, Placebos.

What condition does NCT02993302 study?

NCT02993302 studies Graves Disease.

Is NCT02993302 still recruiting?

NCT02993302 is currently completed. Last updated 21 February 2020.

Are results published for NCT02993302?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-02-21 · How we verify

NCT02993302

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients

Completed Phase 2 Results posted Last updated 21 February 2020

What this trial tests

Phase 2 trial testing 1α-D3 in Graves Disease in 25 participants. Completed in 1 March 2015.

Timeline

1 July 2014

Primary endpoint
1 March 2015

1 March 2015

Quick facts

Lead sponsor	Dr Cipto Mangunkusumo General Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	25
Start date	1 July 2014
Primary completion	1 March 2015
Estimated completion	1 March 2015

Drugs / interventions tested

1α-D3 — full drug profile →
Placebos — full drug profile →

Conditions studied

Graves Disease — all drugs for Graves Disease →

Sponsor

Dr Cipto Mangunkusumo General Hospital

Who can join

18 and older, any sex, with Graves Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

CD80 Level
Time frame: 1 year
Dendritic cells maturation levels were measured by the CD80 (cluster of differentiation 80)
CD206 Level
Time frame: 1 year
Dendritic cells maturation levels were measured by the CD206
IL-12/IL-10 Ratio
Time frame: 1 year
Dendritic cells maturation levels were measured by the IL-12 (interleukin-12)/IL-10 ratio
fT4 Levels
Time frame: 1 year
fT4 (free thyroxine)

Sponsor's own description

Maturity level of dendritic cells (DC) plays a pivotal role in initiating and regulating autoimmunity. In Graves' disease (GD), DCs have more active immune responses than those in healthy subjects. Our previous study demonstrated immunoregulatory effects of in vitro 1,25-D3 on maturation of DC in GD patients. This study aims to evaluate the effect of oral 1α-D3 on DC maturation in GD patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Graves Disease

Currently open trials in the same condition.

NCT07480720 — Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease · recruiting
NCT07305818 — NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease · Phase 1 · recruiting
NCT07286656 — A Study of GensSci098 in Subjects With Graves' Disease · Phase 1 · recruiting
NCT07129642 — Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease · EARLY_PHASE1 · recruiting
NCT07369063 — Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease · Phase 2 · recruiting

Other Dr Cipto Mangunkusumo General Hospital trials

Trials by the same sponsor.

NCT07074548 — Effect of Hydroxytyrosol on NLR, MLR, and SOD in Hypertensive Pregnant Women · NA · completed
NCT07141940 — Indonesian-Language Application-Based Guided Imagery Therapy for Insomnia and Glycemic Control in Diabetic Patients · NA · completed
NCT07422116 — Non-Inferiority Test of Mixsafe® Compared to Neopuff® in Providing Respiratory Support to Neonates · NA · completed
NCT06929793 — Multiple Micronutrients Supplementation on Angiogenesis and Vasculogenesis Factors, and Fetal Biometry · NA · active not recruiting
NCT07149272 — Lactate Kinetics Analysis Related to Low-Intensity Resistance Exercise · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02993302 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr Cipto Mangunkusumo General Hospital
Last refreshed: 21 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02993302.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing